SHOT DOWN: U.S. regulators say that without more data and possibly more patient studies, they can't approve an experimental diabetes pill being developed by Bristol-Myers Squibb and AstraZeneca.
SAFETY CONCERNS: Government advisers last summer said dapagliflozin should not be approved because of risk of breast and bladder cancer, infections and possibly liver damage. The companies say they're committed to the drug.
RIPPLE EFFECT?: Several other companies are testing similar compounds, which likely will be scrutinized to see if they have the same risks.
State Department: Iran Never Signed Nuclear Deal, Which Isn't 'Legally Binding'
'This is not a day care': Oklahoma Wesleyan University president applauded for wake-up call to special snowflakes
WaPo: Let’s hold free speech guilty for the acts of a lunatic, shall we?
Stumbling to War With Russia? | Human Events
- What Is Your U.S. Income Percentile Ranking?
The Cruz Surge Creates GOP Establishment Panic And Paralysis | RedState
NRA Thanks Obama For Signing Pro-Gun Legislation - Bearing Arms - Barack Obama, National Defense Authorization Act